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‘Oketsu’ is a pathophysiologic concept in Japanese traditional (Kampo) medicine, primarily
denoting blood stasis/stagnant syndrome. Here we have explored plasma protein biomarkers
and/or diagnostic algorithms for ‘Oketsu’. Sixteen rheumatoid arthritis (RA) patients were
treated with keishibukuryogan (KBG), a representative Kampo medicine for improving ‘Oketsu’.
Plasma samples were diagnosed as either having an ‘Oketsu’ (n¼19) or ‘non-Oketsu’( n¼29)
state according to Terasawa’s ‘Oketsu’ scoring system. Protein profiles were obtained by
surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF
MS) and hierarchical clustering and decision tree analyses were performed. KBG treatment
for 4 or 12 weeks decreased the ‘Oketsu’ scores significantly. SELDI protein profiles gave
266 protein peaks, whose expression was significantly different between the ‘Oketsu’ and
‘non-Oketsu’ states. Hierarchical clustering gave three major clusters (I, II, III). The majority
(68.4%) of ‘Oketsu’ samples were clustered into one cluster as the principal component of
cluster I. The remaining ‘Oketsu’ profiles constituted a minor component of cluster II and were
all derived from patients cured of the ‘Oketsu’ state at 12 weeks. Construction of the decision
tree addressed the possibility of developing a diagnostic algorithm for ‘Oketsu’. A reduction in
measurement/pre-processing conditions (from 55 to 16) gave a similar outcome in the clustering
and decision tree analyses. The present study suggests that the pathophysiologic concept
of Kampo medicine ‘Oketsu’ has a physical basis in terms of the profile of blood proteins.
It may be possible to establish a set of objective criteria for diagnosing ‘Oketsu’ using a
combination of proteomic and bioinformatics-based classification methods.
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Concepts of ‘Oketsu’ and its Diagnosis
‘Oketsu’, blood stasis or stagnant syndrome, is a
pathophysiologic concept unique to Japanese traditional
(Kampo) medicine (1–3) and is thought to be closely
related to several diseases such as climacteric disorder,
rheumatoid arthritis (RA) (4), Behcet’s disease (5),
hyperuricemia and various inflammatory conditions (6).
Recent reports have suggested that ‘Oketsu’ is correlated
with a deterioration of erythrocyte deformability (7), an
elevation in blood viscosity (8), acceleration of erythro-
cyte aggregation (9), autonomic nervous activity changes
(10) and microcirculatory dysfunction (11). However, a
precise concept of ‘Oketsu’ from the standpoint of
western medicine has yet to be established. Doctors
skilled in Kampo diagnosis and treatment are often able
to improve the symptoms of these blood disorders, which
may be considered to be untreatable by conventional
western therapies. Therefore, if a scientific and objective
standard for diagnosis and treatment of ‘Oketsu’ can be
established, the public will be given greater access to the
beneficial effects of Kampo medicine. Furthermore,
elucidation of the concepts, theory and practice of
Kampo medicines from a scientific and objective view-
point could make a significant contribution to modern
medicine. Although Terasawa et al. (12) have established
criteria for diagnosing ‘Oketsu’ that are made up of
indices of numerous symptom scores, an improved
diagnostic system that eliminates descriptive definitions
involving subjective judgments must be established.
Therefore, it is very important to standardize the
diagnostic criteria for ‘Oketsu’ objectively by using a
universally acceptable scientific method.
Investigation of Biomarkers Using SELDI-TOF MS
Recent advances in mass spectrometry enable high-
throughput profiling of the protein content of complex
mixtures (13). For example, ProteinChip technology
combined with surface-enhanced laser desorption/
ionization time-of-flight mass spectrometry (SELDI-
TOF MS) allows the rapid detection of a wide range of
proteins from a small amount of biologic material. Using
this innovative technology, it is possible to detect changes
in the expression profile of specific proteins of interest
(14,15). Indeed, advances in mass spectrometry are
accelerating the discovery of biomarkers for various
disease states, especially for the detection of several
tumors such as prostate, ovarian and breast cancers
(16–18). Existing diagnostic biomarkers of tumors,
such as ovarian cancer antigen 125 (CA125), are often
inadequate for distinguishing benign from malignant
neoplasm in clinical practice. However, three biomarkers
discovered using the SELDI profiling system have
significantly improved the detection of early stage
ovarian cancer when used in combination with CA125
(16). The diagnosis of a disease using ‘multiple markers’
(i.e. ‘fingerprint analysis’) by employing a combination
of comprehensive high-throughput profiling and
bioinformatics-based discrimination methods is a promis-
ing approach, especially when a single gene aberration or
protein cannot account for all phenotypic forms of the
disease. As is the case with most human cancers, ‘Oketsu’
is subject to individual variation, multifactorial modifica-
tion of the disease state and marked microheterogeneity
of pathogenic molecules. Thus, confirming the diagnosis
of a complex disease that cannot be verified by a single
marker will be extremely useful in clinical practice.
The Aim of This Study
In the present study, we have attempted to establish
‘Oketsu’ biomarkers and/or diagnostic algorithms using
SELDI-TOF MS. RA patients were chosen as subjects
for this study because 53.8% of the RA patients have
‘Oketsu’ syndrome and a clinical relationship exists
between the severity of Terasawa’s ‘Oketsu’ score and
Lansbury’s activity index of RA (4). Keishibukuryogan
(KBG), a representative medicine for the treatment
of ‘Oketsu’ syndrome (19–21), was administered to
16 patients for 12 weeks and the activity of RA, severity
of ‘Oketsu’ and proteomic pattern of plasma at 0, 4 and
12 weeks were evaluated. Clustering analysis and decision
tree construction were performed to classify the ‘Oketsu’
and ‘non-Oketsu’ states. Our results confirm the need to
establish objective criteria for diagnosing ‘Oketsu’ using a
proteomic approach in combination with bioinformatics-
based classification methods.
Methods
Drug: Keishibukuryogan
In Japan, more than 100 Kampo medicines including
KBG have been approved as ethical medicines by the
Ministry of Health, Labor and Welfare of Japan. KBG
has been used for the treatment of gynecologic disorders
such as uterine myoma, climacteric disorder, etc (22–25).
KBG is comprised of five medical plants as follows:
Cinnamomum cassia Blume (Cinnamomi Cortex), Poria
cocos Wolf (Hoelen), Paeonia lactiflora Pallas (Paeoniae
Radix), Prunus persica Batsch (Persicae Semen) and
Paeonia suffruticosa Andrews (Moutan Cortex). These
plants are registered in the Pharmacopoeia of Japan. In
the traditional method of preparing Kampo formulas,
which is even now being used in not just a few hospitals;
the constituent herbs are cut into pieces, mixed according
to the instructions in classical texts, decocted in hot
water and ingested as a liquid extract. In recent years,
464 ‘Oketsu’ diagnosis by SELDI proteomicstechnologic advances have made it possible to manufac-
ture the extract as a spray- or a freeze-dried powder with
high standards of quality, uniformity and stability. KBG
is provided by Tsumura & Co. and several Kampo
manufacturers in Japan. The ultraviolet-visible light
(UV-VIS) profile of three-dimensional (3D) high perfor-
mance liquid chromatography (HPLC) analysis of the
most widely used KBG is shown in Fig. 1.
Subjects and Plasma Samples
We obtained plasma samples from 16 subjects with RA
who visited the Department of Japanese Oriental
Medicine, Toyama Prefectural Central Hospital.
Informed consent was obtained from every subject
prior to the study. All subjects met the American
College of Rheumatology 1987 criteria for the diagnosis
of RA (26). For evaluation of the ‘Oketsu’ state, we
used the ‘Oketsu’ scoring system, with diagnostic criteria
developed by Terasawa et al. (12) (Table 1). This
‘Oketsu’ scoring system consists of 17 inquiries with
three scales of points that are determined after extensive
multivariate analyses; the resultant score in this system
has been reported to have a quantitative relationship
with hemorheology data (7,8,20). Furthermore, analysis
of relationship between this score and the diagnosis of
‘Oketsu’ by traditional Kampo doctors has revealed that
predictive results are obtained depending on the
classification of Oketsu syndrome as of a score of
more than 20 points. Subjects were followed for 12
weeks at an out-patient clinic. After evaluation of the
‘Oketsu’ score (week 0), all of the subjects were treated
with KBG; TJ-25, 2.5 g 3/day for a period of 12
weeks. Some subjects received concomitant disease-
modifying anti-rheumatic drugs (DMARD), non-steroi-
dal anti-inflammatory drugs (NSAID), steroid or other
Kampo medicines for RA. Furthermore, some subjects
were given medicines to control other disease states.
However, only subjects whose condition of disease and
‘Oketsu’ state were relatively stable were selected for the
present study and they remained in a stable condition
with no change in their other medicines or dosage
during the period of study. Therefore, it is highly
probable that the changes that occurred during the
KBG treatment were caused by KBG, although future
studies should be designed to evaluate the pure effect
of KBG. We re-evaluated the ‘Oketsu’ score at 4 and 12
weeks after the commencement of KBG treatment.
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Figure 1. Three-dimensional (3D) HPLC profile of KBG and UV spectra of its constituent crude drugs.
eCAM 2008;5(4) 465Plasma samples were obtained from each subject before
treatment (week 0) and 4 and 12 weeks after treatment
(i.e. a total of 48 plasma samples from 16 subjects).
Samples were stored at  80 C until use.
Sample Preparation for Proteinchip Analysis of Plasma
Unfractionated Plasma
Figure 2A and B illustrates the preparation of unfractio-
nated plasma samples. Plasma samples were thawed and
diluted 1:10 by urea denaturing buffer (7mol/lurea,
2mol/lthiourea, 4% CHAPS, 1% DTT and 2% ampho-
lyte) or PBS buffer.
Anion Exchange Fractionation of Plasma
Plasma samples were separated into four fractions in an
anion exchange resin (Q Ceramic HyperD F resin:
BIOSEPRA) in a 96-well filter plate (Nalge Nunc:
0.45mm pore size) on a vacuum manifold as outlined in
Fig. 2C. Plasma samples were thawed and spun at
20 000g for 15min at 4 C. Twenty microliters of plasma
samples were added to 30ml of U9 buffer (9mol/lurea,
2% CHAPS and 50mmol/l Tris-HCl, pH 9.0) and
vortexed at 4 C for 20min. Fifty microliters of the
diluted plasma sample was applied to each well and 50ml
of U1 buffer (1mol/l urea, 0.22% CHAPS and 50mmol/l
Tris-HCl, pH 9.0) was added. The plate was shaken at
4 C for 30min. Proteins were eluted through the filter by
washes with buffers of different pH. Firstly, after the
flow-through was collected, the resins were incubated
with 100ml of wash buffer (50mmol/l Tris-HCl, pH 9.0,
0.1% N-octylglucopyranoside, OGP) at room tempera-
ture for 10min with shaking. The wash was collected as
‘fraction 1’ (flow-throughþpH 9.0). This procedure was
repeated two times with 100ml each of appropriate buffer
of decreasing pH (pH 5.7 and pH 5.0: 100mmol/l sodium
acetate, 0.1% OGP) to give ‘fraction 2’ and ‘fraction 3’.
The final wash was performed with an organic buffer
containing 33.3% isopropanol, 16.7% acetonitrile and
0.1% trifluoroacetic acid to give ‘fraction 4’.
Proteomic Profiling Using SELDI-TOF MS
Each prepared sample was diluted 1:10 by the
appropriate binding/washing buffers (see below) and
analyzed by four types of ProteinChip (Ciphergen
Biosystems): CM10 (Weak Cation Exchange), Q10
(Strong Anion Exchange), IMAC30 (Immobilized
Metal Affinity Capture coupled with copper) or H50
(Hydrophobic), as shown in Fig. 2. Each array surface
was prepared according to the Ciphergen ProteinChip
Applications guide (27). The binding/washing buffers
for the ProteinChips were 50mmol/l Tris-HCl,
pH 8.0 and 50mmol/l sodium acetate, pH 5.0
(for Q10), 100mmol/l sodium acetate, pH 4.0 (for
CM10), 50mmol/l HEPES, pH 7.0 (for H50) or
100mmol/l sodium phosphate-500mmol/lNaCl, pH 7.0
(for CopperII-IMAC30). The energy-absorbing
molecules (EAM), sinapinic acid (SPA) and a-cyano-
4-hydroxycinnamic acid (CHCA), were applied to each
Table 1. Diagnostic criteria for ‘Oketsu’ syndrome
Symptom Score
Male Female
Dark-rimmed eyes 10 10
Areas of dark pigmentation of facial skin 2 2
Rough skin 2 5
Livid lips 2 2
Livid gingiva 10 5
Livid tongue 10 10
Telangiectasis/vascular spiders 5 5
Subcutaneous hemorrhage 2 10
Palmar erythema 2 5
Resistance and tenderness on pressure
of the left para-umbilical region
55
Resistance and tenderness on pressure
of the right para-umbilical region
10 10
Resistance and tenderness on pressure
of the umbilical region
55
Resistance and/or tenderness on pressure
of the ileo-cecal region
52
Resistance and/or tenderness on pressure
of the sigmoidal region
55
Resistance and/or tenderness on pressure
of the subcostal region
55
Hemorrhoids 10 5
Dysmenorrhea – 10
A total score larger than 20 is diagnosed as an ‘Oketsu’ state and that
not exceeding 20 is diagnosed as a ‘non-Oketsu’ state. Mild symptoms
are designated by half points.
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Figure 2. Flow charts of plasma processing for SELDI
ProteinChip. (A) Unfractionated plasma (Urea) (B) Unfractionated
plasma (PBS) (C) Anion exchange fractionation of plasma. Each
plasma was divided into three aliquots and each aliquot was further
processed according to the procedures denoted by (A), (B), (C).
To cover as wide a range of peaks as possible, combinations of
multiple ProteinChip previously optimized for each sample preparation
were used.
466 ‘Oketsu’ diagnosis by SELDI proteomicsspot in the ProteinChip array. Peptides and proteins
in the m/z (mass/charge) 3000–10 000 range were
ionized with CHCA, whereas those in the m/z
3000–30 000 range were ionized with SPA. For
ionization with SPA, two different intensities of laser
shot were used in order to acquire low (3000–10 000)
and high (10 000–30 000)-mass spectra, which are
designated as ‘SPA-low’ and ‘SPA-high’, respectively.
The ProteinChip arrays were analyzed using a Ciphergen
PBS IIc ProteinChip Reader, which were calibrated
externally using molecular mass standards (Ciphergen
Biosystems).
Analysis of Proteomic Data
All spectra were collected using the ProteinChip software
version 3.1.1 (Ciphergen Biosystems). After smoothing,
baseline subtraction and total ion current normalization,
a proprietary-developed peak detection procedure
(designated as ‘Cross Detector’) was performed for the
spectral data. Firstly, peak screening was performed for
all the spectra. This step provided a reliability score,
representing ‘peak likelihood’, for each of the screened
peaks by assessing the results obtained from plural runs
of an identical peak screening procedure with different
parameter values. Effective peak intervals were deter-
mined based on the cross-spectral density curve of the
reliability score. All the peaks were then redefined
so that each spectrum had one peak in each peak
interval. The peaks obtained by the ‘Cross Detector’
algorithm were separately evaluated by the
Mann–Whitney U-test to examine statistical significance
of the difference in peak intensities between ‘Oketsu’ and
‘non-Oketsu’ states. To avoid harmful effects caused by
multiple testing, we used the false discovery rate (FDR)
for assessment of statistical significance. We adopted
Benjamini and Hochberg’s (28) FDR controlling proce-
dure for FDR estimation and the criterion was set to
FDR50.05.
Clustering and Decision Tree Classification
Spectral data were represented as a proteomic pattern
characterized by the differentially expressed peaks.
We applied a two-way hierarchical clustering method
to those proteomic patterns using Spotfire Decision Site
version 7.2, where the ‘weighted pair group method with
arithmetic mean’ (WPGMA) and Tanimoto distance were
used as a clustering method and similarity metrics,
respectively. The decision tree analysis was performed
as follows. Three decision trees on distinct strategies
were constructed: (i) ordinary C5.0, (ii) PCAþC5.0 and
(iii) C5.0 (high-factor-loading). Strategy (i), ordinary
C5.0, generated a standard decision tree based on the
C5.0 learning algorithm using all of the significantly
differential peaks as candidates for splitters. Meanwhile,
strategy (ii), PCAþC5.0, performed dimension reduction
using Principal Component Analysis (PCA), which
converted higher-dimensional space spanned by differen-
tial peaks into less-redundant and lower-dimensional
space of several principal components. A C5.0 decision
tree with the principal components for splitters was then
generated. The third strategy (iii), C5.0 (high-factor-
loading), also conducted PCA and selected fewer peaks
that had high values of factor loading, which were
obtained through the PCA computation. We selected the
ten highest-factor-loading peaks for each of the principal
components. A C5.0 tree was then constructed using
the high-factor-loading peaks for splitters. We used
Clementine version 7.2 to perform PCA and C5.0 tree
construction.
Statistics
‘Oketsu’ scores are expressed as mean SD. Statistical
analysis was determined by paired t-test with
Bonferroni’s correction for multiple comparisons.
Results
Prevalence of ‘Oketsu’ Syndrome and Improvement of
‘Oketsu’ By KBG
We chose to use the diagnostic criteria of ‘Oketsu’ by
Terasawa et al. (12) (Table 1) because it constituted the
most systematic method of scoring the symptoms. The
oketsu score was evaluated at week 0 (pre-treatment) and
4 and 12 weeks after the commencement of KBG
treatment. The pathophysiologic states of patients were
classified into two categories according to the oketsu
scores of the patients at the time of blood sample
collection: a ‘non-Oketsu’ state (Oketsu score 20)
and an ‘Oketsu’ state (Oketsu score420). Table 2
shows the age/sex distribution of 16 subjects and the
oketsu scores at each time. Ten of 16 patients with
RA (62.5%) were diagnosed as having ‘Oketsu’ at
week 0. This percentage is consistent with the previously
reported incidence of ‘Oketsu’ (53.8%) in RA (4). KBG
treatment for 12 weeks decreased the Oketsu score in 11
of the 16 RA patients, including those in the ‘non-Oketsu’
group. Figure 3 shows the averaged values of the Oketsu
score for all subjects. A significant decrease in the score
was found after 4 and 12 weeks of KBG treatment,
implying an improvement in the ‘Oketsu’ state diagnosed
by Kampo medicine. For proteomic studies, 48 plasma
samples obtained from 16 patients at three time points
(0, 4 and 12 weeks) were independently assigned as
‘Oketsu’ (n¼19) or ‘non-Oketsu’( n¼29) samples accord-
ing to the diagnosis of ‘Oketsu’. Fifty-five SELDI
profiles measured by 55 different conditions and
pre-processing (Methods and Fig. 2) were obtained
from each plasma sample using SELDI-TOF MS
eCAM 2008;5(4) 467proteomics technology. The plasma from each subject
was measured in duplicate on two separate ProteinChip
arrays and treated as independent samples in the
following analyses.
Hierarchical Clustering of 55 SELDI Profiles Classifies
‘Oketsu’ and ‘non-Oketsu’ States
Spectral data were obtained using ProteinChip software
version 3.1.1. Peak detection performed using Biomarker
Wizard software (Ciphergen Biosystems) missed a con-
siderable number of peaks that were found as specific
peaks by manual inspection. We therefore developed
a new algorithm of peak detection, termed ‘Cross
Detector’, based on cross-parametric multiple screening
and cross-spectral reliability density. The Cross Detector
algorithm produced 2596 peaks in a mass range of
3000–30 000 from 5280 SELDI spectra. Our analysis
found 266 peaks that were differentially expressed
between the ‘Oketsu’ and ‘non-Oketsu’ plasma samples.
Next, we performed two-way hierarchical clustering
analysis (two-dimensional WPGMA), based on the 266
peaks and the ‘Oketsu’/’non-Oketsu’ classification. The
clustering algorithm identified three major clusters
(designated as ‘I’, ‘II’, ‘III’ in Fig. 4) in a longitudinal
direction. Clusters I, II and III contained 38, 50 and
8 samples, respectively. Despite the difference in time
points, the six samples obtained from each patient were
clustered at a nearby cluster site. As indicated by the
blue box, 68.4% (26/38) of the ‘Oketsu’ samples were
found in cluster ‘I’. Cluster ‘II’ also contained some
‘Oketsu’ samples (12/38, 31.6%). The ‘Oketsu’ samples
made up 68.4% and 24.0% of clusters ‘I’ and ‘II’,
respectively. Intriguingly, all of the ‘Oketsu’ samples
classified into cluster ‘II’ were derived from patients
showing an improved ‘Oketsu’ state at 12 weeks. Our
data suggest that the ‘Oketsu’ and ‘non-Oketsu’ states can
be classified, at least to a certain extent, into different
groups by clustering analysis of SELDI proteomic
patterns of plasma proteins.
Decision Tree Analysis to Construct a Predictive Model
for ‘Oketsu’
We next investigated whether or not a single peak in the
SELDI profiles can be used as a marker to discern
‘Oketsu’ and ‘non-Oketsu’ plasma samples. However, no
such peaks could be identified. We also performed
multivariate analysis to identify a combination of peaks
that could distinguish between the ‘Oketsu’ and ‘non-
Oketsu’ states using a decision tree classification with
the algorithm C5.0. In general, a decision tree should
be created from a large number of samples and the
generalization error should be estimated using a test set
that is collected independently of the training set.
However, this approach assumes that a large sample
set is readily available. In the present study, because of
limitations in sample acquisition, all 96 samples were
divided into four data sets. Three data sets were used as
the training set for the classifier and the remaining
data set was used to evaluate the generalization error.
The simulation by cross-validation was performed four
times by replacing the test set. The 266 peaks described
previously for the clustering were used to generate the
decision tree. Table 3 shows the average values of
estimated accuracy, sensitivity and specificity obtained
Table 2. Oketsu score and age/sex distribution of subjects
Subject
number
Age Sex Oketsu score Oketsu state/
non-Oketsu
at 0 week
0
week
4
weeks
12
weeks
0W!
12W
1 56 Female 49 32 34 # Oketsu
2 67 Female 35 10 15 # Oketsu
3 65 Female 20 20 20 ! non-Oketsu
4 62 Male 10 10 10 ! non- Oketsu
5 68 Female 17 17 14.5 # non- Oketsu
6 64 Female 15 15 20 " non- Oketsu
7 63 Female 17 17 17 ! non- Oketsu
8 54 Female 27 17 10 # Oketsu
9 54 Female 25 12.5 5 # Oketsu
10 52 Female 25 25 15 # Oketsu
11 70 Male 32.5 17.5 17.5 # Oketsu
12 47 Female 15 15 5 # non- Oketsu
13 69 Female 37 27 15 # Oketsu
14 46 Female 38 27 19.5 # Oketsu
15 79 Male 30 30 25 # Oketsu
16 51 Female 39.5 39.5 44 " Oketsu
#: decrease, !: no change, ": increase.
40
30
10
0
04
Weeks
*
*
O
k
e
t
s
u
 
s
c
o
r
e
12
20
Figure 3. Change in oketsu score after administration of KBG. The
averaged values of oketsu score was evaluated at week 0 (pre-treatment)
and 4 and 12 weeks after the commencement of KBG treatment.
*P50.05 vs week 0, determined by paired t-test with Bonferroni’s
correction for multiple comparison.
468 ‘Oketsu’ diagnosis by SELDI proteomicsfrom the four-fold cross-validation analyses. Analysis by
C5.0 gave an estimated accuracy, sensitivity and specifi-
city of 69.8%, 78.8% and 65.3%, respectively. The best
example of the decision tree is shown in Fig. 5. The tree
used five peaks (m/z 15 955, 8703, 9193, 12 530 and
16 113) to generate six terminal nodes and distinguished
them with 97.2% accuracy in the training set. In the test
set, the tree yielded 83.3% accuracy, 100.0% sensitivity
and 75.0% specificity. Using the same data, we attempted
to improve the accuracy, sensitivity and specificity of the
analysis by using principal component analysis (PCA)
combined with C5.0. Firstly, five principal components of
PCA on the 266 peaks were used to construct the
decision tree with the algorithm C5.0 (PCAþC5.0).
Secondly, ten highest-factor-loading peaks obtained from
PCA were used to construct the decision tree with C5.0
(C5.0þhigh-factor-loading). However, the application of
PCA to tree analysis did not improve the accuracy of the
decision tree based on C5.0. Our results suggest that
classification algorithms to distinguish the ‘Oketsu’ state
from the ‘non-Oketsu’ state based on the SELDI protein
profiling may be established provided that sufficient
samples are analyzed.
Reducing the Measurement Conditions (From 55 to 16)
Gives a Similar Outcome
The measurement of 55 SELDI profiles from a
single sample is both laborious and expensive.
Therefore, we attempted to reduce the number of
measurement conditions. A detailed examination of
the 55 proteomic patterns and 266 detected peaks
suggested that 16 SELDI profiles may be enough to
obtain results compatible with those derived from the
C
l
u
s
t
e
r
i
n
g
 
o
f
 
s
i
g
n
i
f
i
c
a
n
t
 
p
e
a
k
 
i
n
t
e
n
s
i
t
y
clusters I clusters II clusters III
Clustering of plasma samples
Median value
Oketsu sample
1
0
Figure 4. Hierarchical clustering of 55 SELDI profiles. Clustering was based on the 266 differential peaks obtained from 55 SELDI profiles and
‘Oketsu’/ ‘non-Oketsu’ classification. The red (peak maximum¼1) or green (peak minimum¼0) color indicates the relative intensity, i.e. higher than
or lower than the median value (black color), respectively.
Table 3. A comparison of outcome of C5.0 with different features in the
test set (55 SELDI profiles)
classifier Accuracy
(%)
Sensitivity
(%)
Specificity
(%)
C5.0 69.8 78.8 65.3
PCAþC5.0 70.8 59.0 81.5
C5.0 (high-factor-loading) 65.7 74.2 62.0
PCAþC5.0: C5.0 tree constructed with five principal components
obtained by PCA for splitters, C5.0 (high-factor-loading): C5.0 tree
constructed with ten highest-factor-loading peaks for each of the
principal components for splitters.
eCAM 2008;5(4) 46955 profiles. The peak detection algorithm ‘Cross
Detector’ produced 848 peaks from 1536 spectra of 16
SELDI profiles. We found 185 peaks that displayed
significant differential expression between ‘Oketsu’ and
‘non-Oketsu’ states patients. Two-way hierarchical clus-
tering analysis and classification decision tree analysis
were performed using the methods described above.
The result of two-way hierarchical clustering analysis
was similar to that shown in Fig. 4 (73.7% of ‘Oketsu’
samples were clustered together (into ‘I’) as indicated by
a blue box; Fig. 6). The accuracy, sensitivity and
specificity of classification trees based on 16 SELDI
profiles were no less than those based on the 55 profiles
(Table 4). As shown in Fig. 7, the best example of the
C5.0 decision tree used four peaks (m/z 15 955, 8703,
18 612 and 5840) to generate five terminal nodes. These
were distinguished with 97.2% and 83.3% accuracy in
the training set and the test set, respectively. It must
be noted that the decision trees shown in Fig. 5
(55 profiles) and Fig. 7 (16 profiles) both used the same
peaks, m/z 15 955 and 8703, for first and second splitter,
respectively.
Discussion
Kampo medicine is a traditional Japanese medicine.
It originates from a traditional Chinese medicine, but
has developed into a unique form in Japan. Traditional
Chinese and Kampo medicines have special kinds of
medical terminology for the diagnosis and treatment of
diseases and ‘Oketsu’ is one of the pathophysiologic
concepts that have been most frequently used in Kampo
medicine. Ancient Chinese medical texts describe a
disorder of the blood circulation causing various symp-
toms, such as blood stasis, reduced blood flow and
cessation of flow. This phenomenon is called ‘Oketsu’ in
Japanese or ‘Yu Xue’ in Chinese. However, the meaning
of ‘Oketsu’ differs slightly from that of ‘Yu Xue’ and
Oketsu has gained a more important position in Kampo
medicines in Japan. The main cause of the stagnation in
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470 ‘Oketsu’ diagnosis by SELDI proteomicsblood flow leading to ‘Oketsu’ syndrome is thought to be
insufficient exercise or sleep, mental or physical stress,
constipation or a high-calorie diet. At the present time, it
may be not possible to translate ‘Oketsu’ accurately in
terms of Western medicine. However, ‘Oketsu’ is known
to be related to disorders in the peripheral microcircula-
tion, including excessive sensitivity to cold, menstrual
disorder and infertility, as well as refractory diseases,
such as RA, systemic lupus erythematosus (SLE),
disseminated intravascular coagulation (DIC) and various
allergic responses (4,6). Because ‘Oketsu’ is also a concept
denoting ‘the preparatory state for developing recogniz-
able diseases’, the diagnosis and treatment of ‘Oketsu’ not
only will improve the symptoms of the manifest diseases,
but also may prevent the development of these diseases.
Kampo medicines are formulations consisting of crude
drugs that have been used in Japan for thousands of
years for patients with a wide variety of disorders.
Nowadays, more than 100 Kampo medicines have been
approved as ethical medicines by the Ministry of Health,
Labour and Welfare of Japan. The drugs are manufac-
tured on a modern industrial scale in which the quality
and quantity of ingredients are standardized under strict
guidelines. KBG is thought to be one of the most
important prescriptions for improving ‘Oketsu’ syndrome.
KBG has been used for the treatment of various types
and stages of diseases (6,22–25), from the stage prior to
disorder to chronic intractable diseases that are untrea-
table even by a wide array of therapeutic strategies of
modern Western medicine.
In an investigation of the effect of a Kampo medicine
(e.g. KBG) on the ‘symptom’ (e.g. ‘Oketsu’ state)
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Figure 6. Hierarchical clustering of 16 SELDI profiles. Clustering was based on the 185 differential peaks obtained from 16 SELDI profiles and
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Table 4. A comparison of outcome of C5.0 with different features in the
test set (16 SELDI profiles)
Classifier Accuracy
(%)
Sensitivity
(%)
Specificity
(%)
C5.0 75.0 79.6 74.0
PCAþC5.0 72.9 73.3 74.6
C5.0 (high-factor-loading) 66.7 62.7 71.2
PCAþC5.0: C5.0 tree constructed with five principal components
obtained by PCA for splitters, C5.0 (high-factor-loading): C5.0 tree
constructed with ten highest-factor-loading peaks for each of the
principal components for splitters.
eCAM 2008;5(4) 471diagnosed by Kampo medicine, it is difficult to determine
clearly the detailed efficacies and mechanisms of action of
the medicine, because there are often multiple active
ingredients and components and target sites, and mutual
interactions of these multiple components. As described
previously, disease concepts such as ‘Oketsu’ are the
composite of different and multiple symptoms that can
be influenced by environmental and genetic factors.
Therefore, the molecular alterations induced in the
‘Oketsu’ state by KBG, in addition to its efficacy,
would be mediated by complicated set of multimodal
and multifactorial events. Conventional drug research has
mainly focused on the mode of action of a relatively
small number of molecules. Recent advances in ‘‘omics’’
technology have resulted in the development of extremely
high-throughput and comprehensive techniques for func-
tional genomics, proteomics and metabolomics. A power-
ful array of tools is available for investigating the
intricate interplay of different signal-transduction path-
ways in the cell. It is conceivable that these technologies
may offer a crucial contribution to clarification of the
concepts and efficacy of Kampo medicine(s) in terms of
molecular biology.
In the present study, we have investigated the expres-
sion of plasma protein in patients in the ‘Oketsu’ state
by using a proteomics approach. We used the patients’
plasma to analyze protein expression for three
main reasons. Firstly, collection of blood samples is
performed routinely in medical practice and is minimally
invasive. Secondly, the ‘Oketsu’ state is considered to be
closely related to hemorheological and hemostasis
abnormalities. Increases in fibrinogen level, erythrocyte
aggregation and blood viscosity in ‘Oketsu’ syndrome
and their amelioration by KBG treatment have been
reported (8,9,11,19–21). Thirdly, the abnormalities in
hemostasis suggest that there are proteomic changes in
the coagulation-fibrinolytic system in which a massive
proteolysis cascade plays a critically important role.
A cascade of this type may be involved in ‘Oketsu’
syndrome. Therefore, we focused our attention on
the expression of proteins in the plasma rather than
the serum, which is devoid of most of the proteins
involved in the coagulation-fibrinolytic system. Thus, the
adoption of proteomic analysis of plasma in ‘Oketsu’
patients would be reasonable both practically and
theoretically.
The present study demonstrated that the ‘Oketsu’ and
‘non-Oketsu’ states were classified into different clusters
in terms of the plasma protein levels. Hierarchical
clustering, a common method of the clustering analysis
family continuously aggregates similar objects or
‘clusters’ into a larger cluster and eventually generates a
single cluster that contains all objects. Therefore, the
classification is constructed in a tree-like manner and is
represented by a so-called ‘dendrogram’. The similarity
between objects is defined by distance metrics such as
Euclidean distance, Manhattan distance and lots of
other proposed types of metrics. The more similar the
objects/clusters are in the earlier stage, the more they are
merged. In the present study, the objects to be classified
(plasma samples) were represented as a proteomic pattern
characterized by differentially expressed peaks, that is,
an N-dimensional vector whose element values represent
peak intensities. The similarity between two samples was
calculated as the Tanimoto distance between two vectors
of proteomic patterns. By the successive aggregation
of similar samples, we obtained sample classification
(the upper horizontal row in the color map of Fig. 4).
Meanwhile, the given proteomic patterns provided
another set of ‘objects’ to be classified, namely, peaks.
The profile of each peak was composed by the peak
intensities of 96 samples and the similarity of the profiles
among 266 peaks was calculated as described above. By
the successive aggregation of similar peaks, we obtained
peak classification (the left vertical row in the color map
of Fig. 4). Such simultaneous clustering of an identical
data set vertically and horizontally is called ‘two-way
clustering’, an approach that has been reported to have
potentially high performance in the identification of local
groups of genes and/or proteins with similar expression
patterns (29). Our results indicate that a characteristic
proteomic pattern may exist in the plasma of ‘Oketsu’
patients, although a larger-scale clinical trial will be
necessary to validate this finding. Furthermore, the
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472 ‘Oketsu’ diagnosis by SELDI proteomicshierarchical clustering is a heuristic approach but may
not provide any enough ‘‘evidence’’ in principle.
In general, statistical analysis of the world of ‘omics’ is
now being developed. Although there are examples of
statistical analyses of hierarchical clustering, the practical
significance of such analyses is a complex and contro-
versial issue. At present, ‘omics’ approaches are best-
suited to create a new assumption/hypothesis and many
researchers have pointed out that validation studies
should be conducted in separate follow-up studies.
In this case, validation studies with bigger cohorts,
methodologic improvement and strictly defined protocols
will be absolutely necessary, however, should future
studies be undertaken.
Next, to develop a diagnostic criterion for ‘Oketsu’,a
decision tree analysis was performed. A decision tree is a
decision support tool used to identify the strategy most
likely to reach a goal. In the present case, the algorithm
searches and selects a certain SELDI peak as a classifier
that most efficiently splits ‘Oketsu’ samples (420
‘Oketsu’scoring) from ‘non-Oketsu’ samples ( 20
‘Oketsu’ scoring). Usually, the first classifier cannot give
a complete classification. Instead, there is an ‘Oketsu’ -
sample-rich group containing a smaller number of ‘non-
Oketsu’ samples and a ‘non-Oketsu’-sample-rich group
containing a smaller number of ‘Oketsu’ samples. For
each group, the algorithm repeats the search for another
(second) classifier. The combination of the first and
second classifiers thus gives a more accurate classifica-
tion. This process can be repeated until the tree classifies
all of the samples correctly. Thus, the constructed
decision tree gives the most efficient method of the
classification of the given samples and in the next step;
the tree can be used as a predictive model. When a new
sample with SELDI data but without ‘Oketsu’ scores is
given, it can be predicted whether it is ‘Oketsu’ or ‘non-
Oketsu’ by examining the SELDI data in reference to the
decision tree. The decision tree construction in the
present study, however, remains a preliminary trial that
should be improved by large-scale examination. Further
studies with independently collected samples will be
needed to verify the above points. Collectively, our
finding at least addresses the possibility that this ancient
and apparently very speculative concept ‘Oketsu’ might
have a physical basis and that objective criteria for
diagnosing ‘Oketsu’ can be established using a combina-
tion of ProteinChip technology and bioinformatics tools.
Several concerns have been raised related to the present
approach. Firstly, various researchers have pointed out
that, in not a few cases, SELDI-TOF protein patterns in
serum are not reproducible across different experiments
for reasons such as differences in base line correction,
sample preparation protocol, spectrum analysis method,
mass calibration method, etc (30). In preceding studies,
we have tested the effect of the ProteinChip lot, sample
processing, measures taken at different times and
analytical methods and constructed highly standardized
protocols. These protocols contain a reliable peak
detection algorithm (‘Cross Detector’) and robust meth-
ods for selecting significant peaks (‘Peak Separability
Analysis’), which are now patent pending and will be
described in a future paper. Thus, we think that it is
possible that objective criteria for diagnosing ‘Oketsu’ can
be established using a combination of ProteinChip
technology and bioinformatics tools. Ray et al. (31), by
standardizing methodology on sample processing, refer-
ence specimen, acquisition procedure of mass data,
analytical methods, etc. have also demonstrated the
potential of the SELDI platform (ProteinChip) for
reproducible and consistent analysis of serum/plasma
across multiple sites.
Secondly, the availability and reproducibility of
‘profiles’ is highly dependent on the measuring equip-
ment. Extensively standardized equipment, well-validated
protocols and their assured execution are necessary.
In contrast, measuring the concentration of the proteins
identified usually requires relatively low-cost, convenient
and highly reproducible means such as enzyme-linked
immunosorbent assay and enzymatic biochemical analy-
sis. In fact, we have conducted such a study in a
narrower set of subjects with clear-cut symptoms. In that
study, we have identified certain predictive biomarker
proteins for the beneficial effects of KBG in RA
(manuscript in preparation). These markers may be
used to improve the responder rate for KBG in RA
that is closely related to ‘Oketsu’. It may not be hopeful
to identify a single or small number of candidates as
markers for the whole ‘Oketsu’ syndrome, because it is
related to a very broad array of disorders. However, the
identified accumulation of such studies targeted or
limited to subjects with subsets of ‘Oketsu’ syndrome
will largely contribute to delineate the whole picture
of ‘Oketsu’.
In summary, the present study raises the possibility
that objective criteria for diagnosing ‘Oketsu’ can be
established using a combination of ProteinChip technol-
ogy and bioinformatics tools. Further studies will be
required to identify suitable ‘Oketsu’ biomarkers in
detail. Traditional medicine and complementary and
alternative medicine (CAM), which are mainly based on
an empirical approach, have not been fully accepted in
the framework of modern medicine. Problems preventing
the utilization of traditional medicines have been a lack
of sufficient scientific evidence of their efficacy, standard
diagnosis and treatment protocols and communication
procedures through scientifically acceptable language.
The present study may open the way to elucidating
these traditional medical concepts from the viewpoint of
modern science and medicine and may thus lead to the
integration of traditional medicine/CAM and modern
medicine.
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